Every material Form 8-K ROCKET PHARMACEUTICALS, INC. has filed with the SEC since August 27, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Rocket Pharmaceuticals entered a Loan and Security Agreement with Hercules Capital on September 30, 2026, providing up to $150.0 million in senior secured term loans, with $35.0 million funded at closing. The company also issued warrants to the lenders for 1,755,853 shares of common stock at $2.99 per share, which adds potential dilution, and the loans are secured by substantially all of the company's assets.
Tranche 1-A advance of $35.0 million funded September 30, 2026; further tranches total up to $115.0 million at the company's option or the lenders' approval
Loans mature October 1, 2030, with interest at the greater of prime or 6.75%, plus 2.40%
Warrants for 1,755,853 shares at $2.99 per share; 409,699 shares exercisable after the Tranche 1-A funding
Prepayment charges of 3.00%, 2.00% or 1.00% depending on timing; minimum cash covenant not tested while market capitalization exceeds $600.0 million
Rocket Pharmaceuticals said the U.S. Food and Drug Administration confirmed continued enrollment and dosing under a modified protocol for its global pivotal Phase 2 trial of RP-A501 in Danon disease, along with a 12-patient pivotal population and established 12-month co-primary endpoints. The alignment is a regulatory milestone for the program, and the company said it expects to complete dosing of the remaining patients by mid-2027.
FDA confirmed a pivotal population of 12 male patients treated at the recalibrated dose of 3.8 × 10¹³ GC/kg.
The first three patients treated under the modified protocol count toward the 12-patient pivotal population, leaving nine to be enrolled and treated.
Primary assessment at 12 months uses myocardial LAMP2 protein expression and a 10% reduction from baseline in left ventricular mass index as co-primary endpoints.
Rocket plans a Danon disease program webinar on October 6, 2026, at 4:30 p.m. ET.
On August 21, 2026, Rocket Pharmaceuticals adopted a company-wide Severance and Change in Control Program and entered into employment agreements or an amendment with its CEO, General Counsel and Chief Operating Officer. The filing sets out severance levels, including enhanced payments if a termination occurs around a change in control, which define the company's potential payout obligations to these executives.
Program adopted August 21, 2026; CEO receives 15 months base salary without a change in control and 18 months within 12 months after one
CEO Gaurav Shah's agreement sets an annual base salary of $674,856 and a 60% target bonus
General Counsel Martin Wilson's agreement sets an annual base salary of $547,313 and a 45% target bonus
Chief Operating Officer Christopher Stevens' amendment, dated August 21, 2026, amends his July 7, 2025 agreement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ROCKET PHARMACEUTICALS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →